HER-2 Positive Breast Cancer Clinical Trial Using T-DM1 and 89Zr-trastuzumab

- The folks at Jules Bordet Institute are studying the effects of T-DM1; 89Zr-trastuzumab on HER-2 Positive Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start April 2012 and is expected to end circa April 2015.

0032 2 5417314
Geraldine Gebhart, MD
Overall Study Contact Info
StatusName Contact Phone
RecruitingGeraldine Gebhart, MDgeraldine.gebhart@bordet.be0032 2 5417314

This study is officially titled, "Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1."


Universitair Ziekenhuis Antwerpen (UZA)

Antwerpen, Edegem - Recruiting

Institut Jules Bordet

Brussels, Belgium - Recruiting

Vrije Universiteit Amsterdam (VUMC)

Amsterdam, Netherlands - Recruiting

University Medical Center Groningen (UMCG)

Groningen, Netherlands - Recruiting

Radboud University Medical Centre Nijmegen (UMCN)

Nijmegen, Netherlands - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.